Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism

被引:53
|
作者
Louis, JM
Wondrak, EM
Kimmel, AR
Wingfield, PT
Nashed, NT
机构
[1] NIH, Phys Chem Lab, NIDDK, Bethesda, MD 20892 USA
[2] NIH, Cellular & Dev Biol Lab, NIDDK, Bethesda, MD 20892 USA
[3] NIH, Lab Protein Express, NIAMS, Bethesda, MD 20892 USA
[4] NIH, NIDDK, Lab Bioorg Chem, Bethesda, MD 20892 USA
关键词
D O I
10.1074/jbc.274.33.23437
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previously it was demonstrated using a model precursor that processing at the N terminus of the HIV-1 protease (PR) precedes processing at its C terminus. We now show the expression, purification, and kinetics of the autoprocessing reaction of a PR precursor linked to 53 amino acids of the native flanking transframe region (Delta TFP-p6(pol)) of Gag-Pol and containing its two native cleavage sites. The PR contains the two cysteine residues exchanged to alanines, mutations that do not alter the kinetics or the structural stability of the mature PR. Delta TFP-p6(pol)-PR, which encompasses the known PR inhibitor sequence Glu-Asp-Leu within Delta TFP, undergoes cleavage at the Delta TFP/p6(pol) and p6(pol)/PR sites in two consecutive steps to produce the mature PR. Both Delta TFP-p6(pol)-PR and p6(pol)-PR exhibit low intrinsic enzymatic activity. The appearance of the mature PR is accompanied by a large increase in catalytic activity, It follows first-order kinetics in protein concentration with a rate constant of 0.13 +/- 0.01 min(-1) in 0.1 ar acetate at pH 4.8, The pH-rate profile for the observed first-order rate constant is bell-shaped with two ionizable groups of pK(a) 4.9 and 5.1. The rate constant also exhibits approximately 7-fold higher sensitivity to urea denaturation as compared with that of the mature PR, suggesting that the cleavage at the N terminus of the PR domain from the precursor leads to the stabilization of the dimeric structure.
引用
收藏
页码:23437 / 23442
页数:6
相关论文
共 50 条
  • [41] Inhibiting the dimerization of HIV-1 protease
    Zutshi, R
    Shultz, MD
    Ulysse, L
    Lutgring, R
    Bishop, P
    Schweitzer, B
    Vogel, K
    Franciskovich, J
    Wilson, M
    Chmielewski, J
    SYNLETT, 1998, (10) : 1040 - +
  • [42] Cell killing by HIV-1 protease
    Blanco, R
    Carrasco, L
    Ventoso, I
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (02) : 1086 - 1093
  • [43] Endothiopeptide inhibitors of HIV-1 protease
    Yao, S
    Zutshi, R
    Chmielewski, J
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (06) : 699 - 704
  • [44] Dimerization inhibitors of HIV-1 protease
    Boggetto, N
    Reboud-Ravaux, M
    BIOLOGICAL CHEMISTRY, 2002, 383 (09) : 1321 - 1324
  • [45] Rigidity analysis of HIV-1 protease
    Heal, J. W.
    Wells, S. A.
    Jimenez-Roldan, E.
    Freedman, R. F.
    Roemer, R. A.
    CONDENSED MATTER AND MATERIALS PHYSICS CONFERENCE (CMMP10), 2011, 286
  • [46] HIV-1 protease inhibitors in development
    Rusconi, S
    Catamancio, SL
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (03) : 387 - 395
  • [47] PURIFICATION OF RECOMBINANT HIV-1 PROTEASE
    MARGOLIN, N
    DEE, A
    MEI, L
    VLAHOS, CJ
    PREPARATIVE BIOCHEMISTRY, 1991, 21 (2-3): : 163 - 173
  • [48] The active site of HIV-1 protease
    Mager, PP
    MEDICINAL RESEARCH REVIEWS, 2001, 21 (04) : 348 - 353
  • [49] Adaptability and flexibility of HIV-1 protease
    Kumar, M
    Hosur, MV
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 2003, 270 (06): : 1231 - 1239
  • [50] COMPLETE MUTAGENESIS OF THE HIV-1 PROTEASE
    LOEB, DD
    SWANSTROM, R
    EVERITT, L
    MANCHESTER, M
    STAMPER, SE
    HUTCHISON, CA
    NATURE, 1989, 340 (6232) : 397 - 400